Proteolysis targeting chimeric molecules as therapy for multiple myeloma: Efficacy, biomarker and drug combinations
10.3324/haematol.2018.201483
Saved in:
Main Authors: | Lim, S.L., Damnernsawad, A., Shyamsunder, P., Chng, W.J., Han, B.C., Xu, L., Pan, J., Pravin, D.P., Alkan, S., Tyner, J.W., Koeffler, H.P. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
Ferrata Storti Foundation
2021
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/209622 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
by: Lim, S.-L., et al.
Published: (2021) -
The Molecular Biology of Multiple Myeloma
by: Chng, W.J., et al.
Published: (2016) -
Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in t(4;14) multiple myeloma
by: Xie, Z., et al.
Published: (2014) -
miRNA deregulation in multiple myeloma
by: Bi C.L., et al.
Published: (2018) -
Centrosomes and myeloma; aneuploidy and proliferation
by: Chng, W.J., et al.
Published: (2016)